Skip to main content

Advertisement

Table 3 Presentation of major bleeding for rivaroxaban and enoxaparin/VKA patients separately

From: Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

  Rivaroxaban Enoxaparin/VKA
n = 4130 n = 4116
First major bleeding, n (%)   
Any 40 (1.0) 72 (1.7)
Fatal bleeding 3 (<0.1) 8 (0.2)
 Retroperitoneal 0 1 (<0.1)
 Intracranial 2 (<0.1) 4 (0.1)
 Gastrointestinal 1 (<0.1) 2 (<0.1)
 Thorax 0 1 (<0.1)
Nonfatal bleeding in a critical site 10 (0.2) 27 (0.7)
 Retroperitoneal 1 (<0.1) 7 (0.2)
 Intracranial 3 (<0.1) 9 (0.2)
 Intraocular 3 (<0.1) 3 (<0.1)
 Pericardial 0 2 (<0.1)
 Intra-articular 0 4 (0.1)
 Adrenal 1 (<0.1) 0
 Pulmonary 1 (<0.1) 0
 Abdominal 1 (<0.1) 2 (<0.1)
Nonfatal, noncritical site bleeding but associated with a fall in hemoglobin ≥ 2 g/dl and/or transfusions ≥2 units 27 (0.7) 37 (0.9)
 Surgical site 0 3 (<0.1)
 Skin 1 (<0.1) 5 (0.1)
 Urogenital 9 (0.2) 3 (<0.1)*
 Gastrointestinal 14 (0.3) 24 (0.6)
 Nasal 1 (<0.1) 0
 Pulmonary 1 (<0.1) 0
 Intramuscular 1 (<0.1) 2 (<0.1)
  1. VKA, Vitamin K antagonist.
  2. *One patient had a combined gastrointestinal/urogenital bleeding event; this event is counted as gastrointestinal only.